284 related articles for article (PubMed ID: 23904007)
1. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.
Deng B; Sun Z; Jason W; Yang P
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S701-8. PubMed ID: 23904007
[TBL] [Abstract][Full Text] [Related]
2. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
3. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
[TBL] [Abstract][Full Text] [Related]
4. BCAR1 protein plays important roles in carcinogenesis and predicts poor prognosis in non-small-cell lung cancer.
Huang W; Deng B; Wang RW; Tan QY; He Y; Jiang YG; Zhou JH
PLoS One; 2012; 7(4):e36124. PubMed ID: 22558353
[TBL] [Abstract][Full Text] [Related]
5. MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1.
Zheng J; Xu T; Chen F; Zhang Y
Pathol Oncol Res; 2019 Jul; 25(3):1181-1190. PubMed ID: 30637589
[TBL] [Abstract][Full Text] [Related]
6. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
7. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
[TBL] [Abstract][Full Text] [Related]
8. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical significance of miR-139-5p in non-small cell lung cancer.
Yong-Hao Y; Xian-Guo W; Ming X; Jin-Ping Z
J Int Med Res; 2019 Feb; 47(2):867-874. PubMed ID: 30614351
[TBL] [Abstract][Full Text] [Related]
10. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.
Liu XG; Zhu WY; Huang YY; Ma LN; Zhou SQ; Wang YK; Zeng F; Zhou JH; Zhang YK
Med Oncol; 2012 Jun; 29(2):618-26. PubMed ID: 21516486
[TBL] [Abstract][Full Text] [Related]
11. miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC.
Xiao G; Gao X; Sun X; Yang C; Zhang B; Sun R; Huang G; Li X; Liu J; Du N; Liu D; Liang R; Ren H; Qin S
Oncol Rep; 2017 Aug; 38(2):1190-1198. PubMed ID: 28656290
[TBL] [Abstract][Full Text] [Related]
12. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
13. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
Zhou L; Yu L; Zhu B; Wu S; Song W; Gong X; Wang D
BMC Cancer; 2016 Nov; 16(1):876. PubMed ID: 27832750
[TBL] [Abstract][Full Text] [Related]
14. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
16. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer.
Feng A; Tu Z; Yin B
Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258
[TBL] [Abstract][Full Text] [Related]
17. BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma.
Moravcikova E; Krepela E; Donnenberg VS; Donnenberg AD; Benkova K; Rabachini T; Fernandez-Marrero Y; Bachmann D; Kaufmann T
Int J Cancer; 2017 Nov; 141(10):2050-2061. PubMed ID: 28744854
[TBL] [Abstract][Full Text] [Related]
18. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.
Zhang Y; Ma M; Han B
Tumour Biol; 2014 Nov; 35(11):10833-9. PubMed ID: 25081375
[TBL] [Abstract][Full Text] [Related]
19. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.
Han Y; Tian H; Chen P; Lin Q
Oncotarget; 2017 Apr; 8(14):22730-22740. PubMed ID: 28186994
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.
Li H; Zhou RJ; Zhang GQ; Xu JP
Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
